Current usage of pembrolizumab in triple negative breast cancer (TNBC)

References

• Nanda R, Chow LQM, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase IB keynote-012 study. J Clin Oncol. 2016;34(21):2460–2467. doi: 10.1200/JCO.2015.64.8931
   PubMed Web of Science ®Google Scholar
• Geurts V, Kok M. Immunotherapy for metastatic triple negative breast cancer: current paradigm and future approaches. Curr Treat Options Oncol. 2023;24(6):628–643. doi: 10.1007/s11864-023-01069-0
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Buqué A, Kepp O, et al. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015;28(6):690–714. doi: 10.1016/j.ccell.2015.10.012
   PubMed Web of Science ®Google Scholar
• Cortes J, Rugo HS, Cescon DW, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387(3):217–226. doi: 10.1056/NEJMoa2202809
   PubMed Web of Science ®Google Scholar
• Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–2121. doi: 10.1056/NEJMoa1809615
   PubMed Web of Science ®Google Scholar
• Miles D, Gligorov J, André F, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol. 2021;32(8):994–1004. doi: 10.1016/j.annonc.2021.05.801
   PubMed Web of Science ®Google Scholar
• Blackley EF, Loi S. Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC). Breast. 2019;48 (Suppl 1):S44–S48. doi: 10.1016/S0960-9776(19)31122-1
   PubMed Web of Science ®Google Scholar
• Rozenblit M, Huang R, Danziger N, et al. Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers. J Immunother Cancer. 2020;8(2):e001558. doi: 10.1136/jitc-2020-001558
   PubMed Web of Science ®Google Scholar
• Rugo HS, Loi S, Adams S, et al. PD-L1 immunohistochemistry assay comparison in atezolizumab plus nab-paclitaxel–treated advanced triple- negative breast cancer. J Natl Cancer Inst. 2021;113(12):1733–1743. doi: 10.1093/jnci/djab108
   PubMedGoogle Scholar
• Emens LA, Adams S, Barrios CH, et al. First-line atezolizumab plus NAB-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: Impassion130 final overall survival analysis. Ann Oncol. 2021;32(8):983–993. doi: 10.1016/j.annonc.2021.05.355
   PubMed Web of Science ®Google Scholar
• Study of sacituzumab govitecan-hziy and pembrolizumab versus treatment of physician’s choice and pembrolizumab in patients with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer (ASCENT-04) [Internet]. Bethesda (MD): National Library of Medicine Clinicaltrials.gov; 2024 Feb 22 [cited 2024 Feb 28]. Available from: https://clinicaltrials.gov/study/NCT05382286
   Google Scholar
• Yap TA, Bardia A, Dvorkin M, et al. Avelumab plus talazoparib in patients with advanced solid tumors: the JAVELIN PARP medley nonrandomized controlled trial. JAMA Oncol. 2023;9(1):40–50. doi: 10.1001/jamaoncol.2022.5228
   PubMed Web of Science ®Google Scholar
• Bonadio RC, Tarantino P, Testa L, et al. Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: what are the evidences? Cancer Treat Rev. 2022;110:102459. doi: 10.1016/j.ctrv.2022.102459
   PubMed Web of Science ®Google Scholar
• Sikov WM, Polley M-Y, Twohy E, et al. CALGB (Alliance) 40603: long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) ± carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TNBC). J Clin Oncol. 2019;37(Suppl 15):591–591. doi: 10.1200/JCO.2019.37.15_suppl.591
   Google Scholar
• Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–172. doi: 10.1016/S0140-6736(13)62422-8
   PubMed Web of Science ®Google Scholar
• Pusztai L, Denkert C, O’Shaughnessy J, et al. Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: exploratory analysis from KEYNOTE-522. J Clin Oncol. 2022;40(16_suppl):503. doi: 10.1200/JCO.2022.40.16_suppl.503
   Google Scholar
• Yau C, Osdoit M, van der Noordaa M, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2022;23(1):149–160. doi: 10.1016/S1470-2045(21)00589-1
   PubMed Web of Science ®Google Scholar
• Liu J, Blake SJ, Yong MC, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 2016;6(12):1382–1399. doi: 10.1158/2159-8290.CD-16-0577
   PubMed Web of Science ®Google Scholar
• Loi S, Drubay D, Adams S, et al. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol. 2019;37(7):559–569. doi: 10.1200/JCO.18.01010
   PubMed Web of Science ®Google Scholar
• Krishnamoorthy M, Lenehan JG, Maleki Vareki S. Neoadjuvant immunotherapy for high-risk, resectable malignancies: scientific rationale and clinical challenges. J Natl Cancer Inst. 2021;113(7):823–832. doi: 10.1093/jnci/djaa216
   PubMedGoogle Scholar
• Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science. 2020;367(6477). doi: 10.1126/science.aax0182
   PubMed Web of Science ®Google Scholar
• Blank CU, Rozeman EA, Fanchi LF, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med. 2018;24(11):1655–1661. doi: 10.1038/s41591-018-0198-0
   PubMed Web of Science ®Google Scholar
• Ignatiadis M, Bailey A, McArthur H, et al. Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy: interim analysis of the ALEXANDRA/IMpassion030 phase 3 trial. [cited 2024 Feb 22]. Available from: https://atgproductions.net/atgclients/sabcs/2023_SABCS_Abstract_Report-12-3-23.pdf
   Google Scholar
• Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810–821. doi: 10.1056/NEJMoa1910549
   PubMed Web of Science ®Google Scholar
• Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386(6):556–567. doi: 10.1056/NEJMoa2112651
   PubMed Web of Science ®Google Scholar
• Schmid P, Cortés J, Dent RA, et al. LBA18 pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: updated EFS results from the phase III KEYNOTE-522 study. Ann Oncol. 2023;34:S1257. doi: 10.1016/j.annonc.2023.10.008
   Google Scholar
• Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020;396(10257):1090–1100. doi: 10.1016/S0140-6736(20)31953-X
   PubMed Web of Science ®Google Scholar
• Barrios CH, Harbeck N, Zhang HA, et al. Final analysis of the placebo-controlled randomised phase 3 Impassion031 trial evaluating neoadjuvant atezolizumab plus chemotherapy followed by open-label adjuvant atezo in patients with early-stage triple-negative breast cancer. Ann Oncol. 2023;8(1 suppl_4):101220. doi: 10.1016/j.esmoop.2023.101571
   Google Scholar
• Gianni L, Huang C, Egle D, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP michelangelo randomized study. Ann Oncol. 2022;33(5):534–543. doi: 10.1016/j.annonc.2022.02.004
   PubMed Web of Science ®Google Scholar
• Gianni L, Huang C, Egle D, et al. LBA19 event-free survival (EFS) analysis of neoadjuvant taxane/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP michelangelo randomized study. Ann Oncol. 2023;34:S1258–S1259. doi: 10.1016/j.annonc.2023.10.009
   Web of Science ®Google Scholar
• Bianchini G, Huang CS, Egle D, et al. LBA13 tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial. Ann Oncol. 2020;31:S1145–S6. doi: 10.1016/j.annonc.2020.08.2241
   Web of Science ®Google Scholar
• Loibl S, Untch M, Burchardi N, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019;30(8):1279–1288. doi: 10.1093/annonc/mdz158
   PubMed Web of Science ®Google Scholar
• Loibl S, Schneeweiss A, Huober J, et al. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann Oncol. 2022;33(11):1149–1158. doi: 10.1016/j.annonc.2022.07.1940
   PubMed Web of Science ®Google Scholar
• Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010 Jan 1;28(1):105–113. doi: 10.1200/JCO.2009.23.7370
   PubMed Web of Science ®Google Scholar
• Ali HR, Glont SE, Blows FM, et al. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Ann Oncol. 2015;26(7):1488–1493. doi: 10.1093/annonc/mdv192
   PubMed Web of Science ®Google Scholar
• Szekely B, Bossuyt V, Li X, et al. Immunological differences between primary and metastatic breast cancer. Ann Oncol. 2018;29(11):2232–2239. doi: 10.1093/annonc/mdy399
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci A. Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond, expert opin investig drugs. Expert Opin Investig Drugs. 2022;31(6):6, 549–555. doi: 10.1080/13543784.2022.2008354
   PubMed Web of Science ®Google Scholar
• Vs P. Observation in people with triple-negative breast cancer who had a pathologic complete response after chemotherapy plus pembrolizumab [Internet]. Bethesda (MD): National Library of Medicine Clinicaltrials.gov; 2024 Feb 20 [cited 2024 Feb 25]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT05812807
   Google Scholar
• Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147–2159. doi: 10.1056/NEJMoa1612645
   PubMed Web of Science ®Google Scholar
• Shah AN, Flaum L, Helenowski I, et al. Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer. J Immunother Cancer. 2020;8(1):e000173. doi: 10.1136/jitc-2019-000173
   PubMed Web of Science ®Google Scholar
• Page DB, Pucilowska J, Bennetts L, et al. Abstract P2-09-03: updated efficacy of first or second-line pembrolizumab (pembro) plus capecitabine (cape) in metastatic triple negative breast cancer (mTNBC) and correlations with baseline lymphocyte and naïve CD4+ T-cell count. Cancer Res. 2019;79(4_Supplement):P2–09–03–P2–09–03. doi: 10.1158/1538-7445.SABCS18-P2-09-03
   Web of Science ®Google Scholar
• Tutt AN, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1-or BRCA2-mutated breast cancer. N Engl J Med. 2012;384(25):2394–2405. doi: 10.1056/NEJMoa2105215
   Google Scholar
• Wu Z, Cui P, Tao H, et al. The synergistic effect of PARP inhibitors and immune checkpoint inhibitors. Clin Med Insights Oncol. 2021 Feb 25;15:1179554921996288.
   Web of Science ®Google Scholar
• Vinayak S, Tolaney SM, Schwartzberg L, et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol. 2019;5(8):1132–1140. doi: 10.1001/jamaoncol.2019.1029
   PubMed Web of Science ®Google Scholar
• Domchek SM, Postel-Vinay S, Im SA, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol. 2020;21(9):1155–1164. doi: 10.1016/S1470-2045(20)30324-7
   PubMed Web of Science ®Google Scholar
• Litton JK, Beck JT, Jones JM, et al. Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: results of a phase ii study. Oncology. 2023 Oct 3;28(10):845–855. doi: 10.1093/oncolo/oyad139
   Google Scholar
• Study of sacituzumab govitecan-hziy and pembrolizumab versus treatment of physician’s choice in patients with triple negative breast cancer who have residual invasive disease after surgery and neoadjuvant therapy (ASCENT-05) [Internet]. Bethesda (MD): National Library of Medicine Clinicaltrials.gov; 2024 Feb 13 [cited 2024 Feb 22]. Available from: https://clinicaltrials.gov/study/NCT05633654
   Google Scholar
• Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab Govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021 Apr;384(16):1529–1541.
   PubMed Web of Science ®Google Scholar
• Iwai T, Sugimoto M, Wakita D, et al. Topoisomerase I inhibitor, irinotecan, depletes regulatory T cells and up-regulates MHC class I and PD-L1 expression, resulting in a supra-additive antitumor effect when combined with anti-PD-L1 antibodies. Oncotarget. 2018;9(59):31411–31421. doi: 10.18632/oncotarget.25830
   PubMedGoogle Scholar
• A study of dato-DXd with or without durvalumab versus investigator’s choice of therapy in patients with stage I-III triple-negative breast cancer without pathological complete response following neoadjuvant therapy (TROPION-Breast03) [Internet]. Bethesda (MD): National Library of Medicine Clinicaltrials.gov; 2024 Feb 13 [cited 2024 Feb 22]. Available from: https://www.clinicaltrials.gov/study/NCT05629585
   Google Scholar
• Dixon-Douglas J, Loi S. Immunotherapy in early-stage triple-negative breast cancer: where are we now and where are we headed? Curr Treat Options Oncol. 2023;24(8):1004–1020.
   PubMed Web of Science ®Google Scholar
• Loibl S, O’Shaughnessy J, Untch M, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (brightness): a randomized, phase 3 trial. Lancet Onco. 2018;19(4):497–509. doi: 10.1016/S1470-2045(18)30111-6
   PubMed Web of Science ®Google Scholar
• Sharma P, Stecklein SR, Yoder R, et al. Clinical and biomarker findings of neoadjuvant pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer: NeoPACT phase 2 clinical trial. JAMA Oncol. 2024 Feb 1;10(2):227–235. doi: 10.1001/jamaoncol.2023.5033
   PubMed Web of Science ®Google Scholar